Who are Iopamidol 370 mgI/mL's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Iopromide (Ultravist), Ioversol 320 mgI/mL, Iopamidol 370 mgI/dL.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iopamidol-370-mgi-ml.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Iopamidol 370 mgI/mL — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Iopamidol 370 mgI/mL (Iopamidol 370 mgI/mL) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-ionic iodinated contrast medium. Area: Diagnostic Imaging.

marketed Non-ionic iodinated contrast medium Diagnostic Imaging Small molecule Live · refreshed every 30 min

Target snapshot

Iopamidol 370 mgI/mL (Iopamidol 370 mgI/mL) — Bracco Diagnostics, Inc. Iopamidol is a non-ionic iodinated contrast medium that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Iopamidol 370 mgI/mL TARGET	Iopamidol 370 mgI/mL	Bracco Diagnostics, Inc	marketed	Non-ionic iodinated contrast medium
Iopromide (Ultravist)	Iopromide (Ultravist)	Chinese PLA General Hospital	marketed	Non-ionic iodinated contrast medium
Ioversol 320 mgI/mL	Ioversol 320 mgI/mL	Guerbet	marketed	Non-ionic iodinated contrast medium
Iopamidol 370 mgI/dL	Iopamidol 370 mgI/dL	Bracco Diagnostics, Inc	marketed	Non-ionic iodinated contrast medium

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-ionic iodinated contrast medium class)

Bracco Diagnostics, Inc · 2 drugs in this class
Chinese PLA General Hospital · 1 drug in this class
Guerbet · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Iopamidol 370 mgI/mL — Competitive Intelligence Brief. https://druglandscape.com/ci/iopamidol-370-mgi-ml. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab